Kenya's Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market is expected to grow from $21 Mn in 2022 to $40 Mn in 2030 with a CAGR of 8.6% for the year 2022-2030. Improving health infrastructure and novel therapeutic options for the treatment of ADHD in Kenya are the major factors responsible for the growth of the market. The Kenya ADHD therapeutics market is segmented by drug, drug type, demographics, and by distribution channel. Some of the major players in the market include Dinlas Pharma, Afinus Pharma, and Eli Lily.
The Kenya Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market size is at around $21 Mn in 2022 and is projected to reach $40 Mn in 2030, exhibiting a CAGR of 8.6% during the forecast period. Ukur Yatani, the National Treasury Cabinet Secretary for Kenya, has declared a $1.27 Bn allocation for the healthcare sector in the 2022–23 fiscal year, of which $540 Mn will go toward Universal Health Coverage (UHC). The free maternity program, which presently provides benefits to over 1 Mn mothers annually, the expansion of the volume of health workers in both the public and private sectors, and the establishment of a digital health platform that effectively monitors the health sector are important UHC initiatives. Yatani stated that $61 Mn was used to purchase COVID-19 vaccines, and $36 Mn was given to the free maternity services program in order to support activities and programs aimed at achieving universal health coverage.
ADHD is a developmental disorder that manifests as attentional issues, impulsive behavior, and hyperactivity. Its symptoms typically begin in infancy but, as is now known, can continue into adolescence and adulthood. According to research conducted by several Kenyan clinicians, the prevalence of ADHD cases has increased from 18% to 45%. The Vanderbilt Assessment Scale was one of many tests administered as part of the study to kids who had been brought to the hospital by their parents. According to the study, the following were the major factors that led kids and/or teens to the hospital: Failures and demands at school, Violence and aggressive conduct, and High-risk behaviors in pre-teenagers and adolescents. Oppositional defiant disorder and ADHD are co-morbid disorders that are linked to more severe clinical states and less favorable outcomes. In some instances, ADHD is linked to antisocial behavior, and when these disorders coexist, the prognosis is worse and is linked to neurocognitive deficits than when they are separate.
The class of ADHD medications that are most frequently given in Kenya are central nervous system (CNS) stimulants. Dopamine and norepinephrine, two brain chemicals, are increased in greater quantities by these medications. These stimulants have a paradoxical calming impact on ADHD patients. Many people experience a decrease in hyperactivity and an increase in attention span as a consequence of this. Their focus and concentration are enhanced by the impact. Typical CNS drugs for the treatment of ADHD include compounds based on amphetamine (Adderall, Dexedrine, DextroStat), Dexmethylphenidate (Focalin), methylphenidate, and dextromethamphetamine (Concerta, Daytrana, Metadate, Ritalin). Some non-stimulants function by raising the brain's norepinephrine levels. Norepinephrine is believed to improve memory and focus. Non-stimulant treatments include atomoxetine (Strattera), and antidepressants like nortriptyline (Pamelor).
Market Growth Drivers
ADHD diagnosis is getting better as medical facilities get more sophisticated and available in Kenya. This indicates that more individuals are receiving the disorder's diagnosis, which is fuelling the Kenya ADHD therapeutics market expansion. Non-stimulant medications, cognitive behavioral therapy, and neurofeedback are a few of the novel treatments for ADHD. The market for ADHD is expanding as a result of the increased accessibility of these therapies in Kenya.
Market Restraints
Due to their high cost, many ADHD medicines may only be available to those who can afford them. This might slow the Kenya ADHD therapeutics market's expansion. The inability of Kenyan healthcare facilities to identify and treat ADHD may be due to a lack of appropriately qualified healthcare workers. This might restrict the market's expansion for ADHD medications. Although Kenyans are becoming more aware of ADHD, many medical professionals still lack the skills and education necessary to correctly identify and treat the disorder. This might restrict the Kenya ADHD therapeutics market from expanding.
Key Players
The governing body in charge of regulating and registering medications in Kenya is the Pharmacy and Poisons Board (PPB). The PPB is in charge of making certain that all medications, including those used to treat ADHD, are secure, efficient, and of the highest caliber. All medications used in Kenya, including those used to address ADHD, must be registered with the PPB. A drug must undergo a thorough evaluation procedure to confirm its effectiveness and safety before it can be registered. In Kenya, the PPB is in charge of upholding drug laws. This involves taking legal action against drug distributors and manufacturers who disobey the law. The PPB is in charge of informing the public about the medications that are sold in Kenya. This includes instructions on how to use medications safely and any possible adverse effects.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Drug Type (Revenue, USD Billion):
By Age Group (Revenue, USD Billion):
By Distribution Channel (Revenue, USD Billion):
By Psychotherapy (Revenue, USD Billion):
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.